跳至主要内容
临床试验/NL-OMON25748
NL-OMON25748Other不适用

A Phase 1, Single-Center, Single-Blind, Placebo and Propofol Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous (IV) Infusion Doses of ABP-700

Annovation Biopharma, University Medical Center Groningen (UMCG)0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
Other
发起方
入组人数
48

研究概览

简要总结

one

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Healthy, adult, men and women, 18-45 years of age, inclusive.
  • 2.Continuous non-smoker who has not used nicotine-containing products for at least 6 months prior to the first dose.

排除标准

  • 1. History or presence of significant cardiovascular disease, or cardiovascular disease risk factors, hyperlipidemia, coronary artery disease, or any known genetic pre disposition to cardiac arrhythmia (including long QT syndrome.).
  • 2.History or presence of significant pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological (inclusive of any seizure disorder), or psychiatric disease.

研究者

发起方
Annovation Biopharma, University Medical Center Groningen (UMCG)

相似试验